Oxurion NV — Major Shareholding Notification 2025

Apr 2, 2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – April 2, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on April 1, 2025, from Atlas Special Opportunities II, LLC indicating that as of March 31, 2025, it held 925,088 shares of the then outstanding 4,634,663 shares, and therefore crossed under the threshold (20%) by virtue of the selling of voting securities.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA MARKETS AUTHORITY	FINANCIAL SERVICES AND		Form TR-1 BE PARTI	Transparency notification
1) Status of the notification
	Final
2) Issuer
ldentification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entities)
	Atlas Special Opportunities II LLC			2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of votinq rights (only to be filled in if art. 7 of the Law applies)
	Name			Address (for legal entities)
	Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6			Part II
7) Date on which the threshold is crossed
31/03/2025 (DD/MMYYYY)
8) Threshold that is crossed (in %)
20
	If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
		4,634,663
	Please enter the denominator before filling in the data
10) Notified details
A) Voting rights		Previous notification After the transaction
	# of voting rights			# of voting rights Not linked to the		% of voting rights Not linked to the
Holders of voting rights			Linked to securities	securities	Linked to securities	securities

B) Equivalent financial instruments	After the transaction
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
1	The totals will be updated once you have clicked on
	TOTAL (A & B)			# of voting rights	% of voting rights
			CALCULATE	925,088	19.96%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.
12) In case of proxy voting for only one GM
will cease to hold / Holder will hold again	(DD/MM/YYYY) voting rights as of
13) Additional information
On 21 March 2025 (with settenerit date on 25 March 11 LC sod 45 stares in Oxiron NY, as a result which its stareholding decreased of 1,06,069 shares in 1,06 ( denominator = 4,634,663). On. 26 March 2025 (with settement at an 2025), Mas Special Operaniiss II L.C sold 10,949 stares of Writtin starending decreased 0 99,19 stares (2 99,19 stares (2 99,19 stares denominator = 4,634,663). On 26 March 2025 (with settlement date on 20 March 11 LC sol 28,225 stares in Orains N , as a result of Mith its starending decreased o 66,000 shares (= 2.0.89%, denominator = 4,634,663). On 21 March 2025 (with ethement date on 31 March 2021) 13,02 shares in Orainn N , as a result of which its stares of 92,008 shares (= 19.9%, denominator = 4,634,663).

	Done at New York
On	31/03/2025	(DD/MMYYYY)
	Name & capacity Patrick Vance, Proxyholder

Signature | Patvick Varie

For security reasons, the unsigned form in xlsx format should be
transmitted to trp.fin@fsma.be. You can do this manually
OR if you have MS Outlook at your disposal via t

In addition, a signed copy in PDE format should also be
transmitted.